Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis

The main aim of this study is to investigate whether baseline lactate dehydrogenase (LDH) is associated with the clinical outcome of non small‐cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We searched Pubmed, the Cochrane Central library and Embase for periphera...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2019-04, Vol.8 (4), p.1467-1473
Main Authors: Zhang, Zhibo, Li, Ye, Yan, Xiang, Song, Qi, Wang, Guoqiang, Hu, Yi, Jiao, Shunchang, Wang, Jinliang
Format: Article
Language:English
Subjects:
Bias
Biomarkers
Biomarkers, Tumor - blood
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - enzymology
Clinical Cancer Research
Dehydrogenases
Female
Gene Expression Regulation, Neoplastic
Humans
Immune checkpoint inhibitors
Immunotherapy
Immunotherapy - methods
L-Lactate dehydrogenase
L-Lactate Dehydrogenase - blood
Lactic acid
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - enzymology
Male
Medical prognosis
Meta-analysis
Multivariate analysis
Neutrophil-to-lymphocyte ratio
Neutrophils
Non-small cell lung cancer
Non-small cell lung carcinoma
Original Research
Patients
Peripheral blood
Peripheral blood biomarker
Prognosis
Quality
Researchers
Studies
Survival Analysis
Treatment Outcome
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The main aim of this study is to investigate whether baseline lactate dehydrogenase (LDH) is associated with the clinical outcome of non small‐cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We searched Pubmed, the Cochrane Central library and Embase for peripheral blood biomarker of LDH in advanced NSCLC patients treated with ICIs. We extracted the hazard ratio (HR) with 95% confidence interval (CI) for the progression free survival (PFS) and overall survival (OS) and performed meta‐analysis of HR. Pooled estimates of treatment outcomes were calculated by stata 15.1. Six studies with 1136 patients were included in this study. The pooled results of univariate analysis suggested that an elevated pretreatment LDH level was correlated with significant shorter PFS (HR = 1.53, 95% CI 1.27‐1.83, P 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.2024